The European Medical Device Ecosystem: Interactions Between Regulation, Innovation, Market Access, and Healthcare Systems

The European Union medical device sector is analysed in several largely separate literatures: regulatory studies of the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR), innovation research on individual technology classes, commercial market reporting, and health-policy work on adoption and reimbursement. Integration across these dimensions is limited, so the mechanisms by which regulatory change propagates into innovation, market access and healthcare-system outcomes remain poorly specified. This review addresses that gap by proposing and applying a five-stage conceptual framework: Regulation, Evidence, Innovation, Market Access, Healthcare-System Impact, and by using it to structure a reproducible literature synthesis. Four bibliographic databases and a defined set of institutional sources were searched for the period January 2017 to June 2026, with the geographical scope restricted to the EU-27 and the EEA; identified records were screened against explicit criteria and the retained documents were coded against the five framework dimensions. Rather than reporting market values as isolated figures, the synthesis examines relationships between certification duration, evidence intensity, segment growth, market concentration and access conditions. Three findings emerge. First, segment growth in the EU market is ordered by evidence intensity rather than by technological novelty alone: the innovation-intensive segments that grow fastest are also those with the longest and most variable certification paths, median application-to-certificate durations being approximately 17–19 months for in vitro diagnostics and 19–22 months for medical devices, so that regulation operates as a selection mechanism on who can participate rather than as a uniform brake on growth. Second, the innovation consequence of regulatory delay has moved from assertion to estimation: a two-market economic model attributes a measurable loss of EU-directed development effort to the absence of patent-term compensation for conformity assessment, and manufacturer survey evidence records a reallocation of first approvals and launches away from the EU. Third, December 2025 targeted revision of the MDR and IVDR, the first joint clinical assessments of high-risk devices in 2026, and the phased mandatory use of EUDAMED constitute a partial correction whose effects are not yet observable. The framework identifies where regulatory change translates into consequences for manufacturers, providers and patients, and shows that the chain is well evidenced at its regulatory origin and weakest at its healthcare-system terminus.